AML
The targeted therapy of FLT3-ITD-positive AML with ponatinib might be associated with a lower frequency of secondary resistance caused by acquired FLT3-TKD mutations.
The targeted therapy of <span class="gene" id="22409268-8-24-28">FLT3</span>-ITD-positive <span class="disease" id="22409268-8-42-45">AML</span> with ponatinib might be associated with a lower frequency of secondary resistance caused by acquired <span class="gene" id="22409268-8-147-151">FLT3</span>-TKD mutations.